Overview

A Prospective Clinical Trial in Chronic Hepatitis B Patients NAs (Nucleotides or Nucleosides) Experienced (Anchor Study)

Status:
Unknown status

Trial end date:
2019-06-01

Target enrollment:

Participant gender:

Summary

This study is a multi-center, randomized, prospective, open-label Phase III Clinical trial to assess the efficacy and safety of combination and sequential treatment with Y peginterferon Alfa-2b,entecavir and GMCSF in chronic hepatitis B patients nucleotides or nucleosides experienced. Patients were randomized to one of 3 groups to receive different antiviral treatment.

Phase:

Phase 3

Details

Lead Sponsor:

Tongji Hospital

Collaborator:

Xiamen Amoytop Biotech Co., Ltd.

Treatments:

Adefovir
Adefovir dipivoxil
Entecavir
Interferon-alpha
Molgramostim
Peginterferon alfa-2b
Sargramostim